What are the new targeted drugs for kidney cancer

A new kidney cancer drug called "sorafenib" uses a "multi-target" approach to attack cancer cells and has shown good efficacy in clinical trials, indicating that cancer treatment is entering the multi-target era.

1. Basic concepts of tumor targeted therapy

Targeted therapy is divided into three levels. The first is to target a certain organ. For example, a certain drug is only effective for tumors in a certain organ. This is called organ targeting. The second is cell targeting. As the name suggests, it refers to targeting only a certain type of tumor cells. After entering the body, the drug can selectively bind to this type of cell, thereby causing cell apoptosis. The third is molecular targeting, which is to select tumor cell-specific targets and use drugs targeting the target for treatment, thereby avoiding damage to normal cells and achieving the goal of high efficiency and low toxicity. Molecular targeted therapy is a "bright spot" in current tumor treatment. With its specificity and effectiveness, it has achieved great success and is currently a "hot spot" for treatment at home and abroad.

Molecular targeting is the highest level of specificity in targeted therapy. Molecular targeted therapy is a new biological treatment model that targets the links that may lead to cell canceration, such as cell signal transduction pathways, proto-oncogenes and tumor suppressor genes, cytokines and receptors, anti-tumor angiogenesis, suicide genes, etc., to reverse this malignant biological behavior at the molecular level, thereby inhibiting the growth of tumor cells and even causing them to completely disappear. Commonly used therapeutic targets for tumor molecular targeted therapy include: cell receptors, signal transduction and anti-angiogenesis, etc. There are two main types of such drugs, monoclonal antibodies and small molecule compounds.

2. Basic procedures for molecular targeted diagnosis and treatment of tumors

First, we collect samples through surgical biopsy, puncture biopsy, microscopic sampling, extraction of effusion and collection of exfoliated cells in body fluids, and then use conventional pathology, immunohistochemistry, gene mutation, Southern, PCR, ELISH, FISH, CISH, etc. to complete tissue cytology examination and consultation to determine the tumor type. At the same time, we complete targeted molecular pathology index examinations.

3. Sorafenib, a new drug for kidney cancer, enters the era of "multi-target"

Earlier this month, French cancer experts said at the European Oncology Congress held in Paris that a new kidney cancer drug called "sorafenib" uses a "multi-target" approach to attack cancer cells and has shown good efficacy in clinical trials, marking that cancer treatment is entering the multi-target era.

According to a recent report by French media, "Sorafenib" was jointly developed by Bayer Healthcare and other companies in Germany. Professor Escudil of the Gustave Lucey Institute, the largest cancer research institution in Europe, and other experts introduced at the European Cancer Conference that this new drug has been proven to have significant efficacy in advanced renal cell carcinoma. The latest interim analysis results of the Phase III clinical trial showed that compared with patients taking placebo, the use of "Sorafenib" treatment can extend the patient's progression-free survival by 1 time. The so-called progression-free survival refers to the time a patient survives without obvious tumor growth.